1.Clinical study of thermotherapy with chemotherapy in advanced non-small cell lung cancer with neuroendocrine differentiation
Chinese Journal of Primary Medicine and Pharmacy 2014;21(12):1787-1788
Objective To study the clinical efficacy of thermotherapy combined chemotherapy in the treatment of the advanced non-small cell lung carcinoma with neuroendocrine differentiation (NSCLC-NED).Methods The clinical data of 16 patients with NSCLC-NED were retrospectively reviewed.To analyzed the efficacy and survival of these patients.All patients were treated by thermotherapy with the combined chemotherapy regiment of platinum agents.Results There were 7 partial responses and 4 stable disease,The overall response rate (RR) was 43.8%.The one year survival rate was 37.5% (6/16).The improvement rate of quality of life was 62.5% (10/16).Conclusion Neuroendocrine differentiation is an important indicator of biological behavior of NSCLC.Thermochemotherapy is an active regimen in the advanced NSCLC-NED with an acceptabe toxicity.
3.All-transretinoic acid combined with arsenious acid and chemotherapy in the treatment of acute promyelocytic leukemia patients with 10 years for survival
Yanshun ZHANG ; Jin WANG ; Yong WANG
Chinese Journal of Primary Medicine and Pharmacy 2016;23(17):2645-2648
Objective To study the curative effect and characteristics of all -transretinoic acid (ATRA) and arsenic acid (As2 O3 )combination chemotherapy for acute promyelocytic leukemia (APL).Methods ATRA (30 -60mg/d),As2 O3 (0.1%As2 O3 d1 -28),chemotherapy(anthracycline -based chemotherapy regimens and homoharringtonine -based chemotherapy regimens or high -doses of cytosine arabinoside and small -doses of metho-trexate)were used alternately 4 -5 cycles.Results 12 cases had complete response(CR),CR rate was 100%,first cases and relapse cases all got CR,the median time needed 30 days to get CR.Follow -up deadline,all cases 10 year disease -free survival (DFS )rate was 100%,all reexamination minimal residual disease (MRD)was negative. Conclusion Using this method to treat adult APL,the CR rate is high,has less adverse reaction,and did not produce resistance phenomenon.It can be used for APL consolidation and maintenance therapy.This is one of the ways that can be recommended in the treatment.
4.Clinical study on Yinzhi-huang combined with probiotics in the treatment of neonatal hyperbilirubinemia
Yanshun MU ; Huaaling LIU ; Dongmei SONG ; Dongjie ZHANG
International Journal of Traditional Chinese Medicine 2013;35(12):1068-1070
Objective To investigate the therapeutic efficacy of Yinzhi-huang combined with probiotics in the treatment of neonatal hyperbilirubinemia.Methods 80 neonates of hyperbilirubinemia were recruited into a treatment group (40 cases) and a control group (40 cases).The control group was treated with the gap blue light irradiation,besides,patients with rapid increase or high level of bilirubin were additionally treated with acid-correcting agents,Liver enzyme inducer,and albumin infusion; while the treatment group was additionally treated with Yinzhi-huang and probiotics on the basis of the control group.The values of serum total bilirubin before the treatment Was determined in both groups.During treatment,the changes of daily bilirubin,were monitored with percutaneous bilirubin monitor,and the time for serum bilirubin values decreased to normal level was studied in both groups.Results The two groups showed no significant difference in examination of the serum bilirubin values before treatment(P>0.05).The daily bilirubin decreased value of treatment group(53.07± 17.80) μmol/L showed statistically significant compared with the control group(30.56± 13.43)μmol/L(P<0.05); the time for serum bilirubin values decreased to normal level in the treatment group (4.87± 2.06) d was significantly different compared with the control group (7.12± 2.33) d,(P< 0.05).The apparent effective rate in the treatment group 75% (30/40) was higher than that in the control group 35%(14/40)with statistical significance(x2=5.89,P<0.05).The total effective rate in the treatment group 92.5% (37/40)was higher than the control group 75% (30/40)with statistical significance (x2=4.50,P<0.05).Conclusion Yinzhi-huang combined with probiotics has better effects than conventional treatment in decreasing the daily bilirubin values,restoring normal serum bilirubin time of neonatal hyperbilirubinemia and it is worthy of clinical application.
5.The sequencing analyze of 915 newborn with GJB2 heterozygous mutation in Beijing.
CUI QINGJIA ; HUANG LIHUI ; RUAN YU ; DU YANSHUN ; ZHAO LIPING ; YANG JUN ; ZHANG WEI
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2015;29(13):1164-1167
OBJECTIVE:
To determine GJB2 allelic mutant and estimate probability of hereditary hearing loss in newborn with GJB2 heterozygous mutation in Beijing.
METHOD:
We performed genetic testing for sequencing of GJB2 gene for searching GJB2 allelic mutant in 915 newborn who received newborn deafness gene screening (GJB2 c. 235delC, GJB2 c. 299_300delAT, GJB2 c. 176191del16, GJB2 c. 35delG) in Beijing Tongren hospital, and the mutation were classified to pathogenic mutation,undefined variant and polymorphism.
RESULT:
Four hundred (43.72%, 400/915) newborn were detected to carry at least one mutation allele in GJB2. 3 (0.33%, 3/915) newborn had pathogenic mutations (c. 94C>T, c. 380G>T, c. 344T>G); 62 (6.76%, 62/915) newborn carried 14 undefined variant, 36 newborn had c. 109G>A (58.06%, 36/62),13 newborn had c. 368C>A (20.97%,13/62), six (c. 268C>G, c. 282C>T, c. 294G>C, 456C>T, c. 501G>A, c. 587T>C) are novel; 335 (36.61%, 335/915) newborn were polymorphism.
CONCLUSION
The probability of hereditary hearing loss is 7.09% in newborn with GJB2 heterozygous mutation in Beijing. It is noteworthy that c. 109G>A, c. 368C>A occupy a high proportion.
Alleles
;
Beijing
;
Connexin 26
;
Connexins
;
genetics
;
DNA Mutational Analysis
;
Deafness
;
genetics
;
Genetic Testing
;
Heterozygote
;
Humans
;
Infant, Newborn
;
Mutation
;
Neonatal Screening
;
Polymorphism, Genetic
6.Analyzing the current status of newly diagnosed occupational pneumoconiosis patients in Zhangdian District of Zibo City
Chunmei JIANG ; Jihu YI ; Yanshun SUN ; Jinlong MEN ; Cheng ZHANG
China Occupational Medicine 2023;50(3):330-334
Objective To analyze the distribution, survival conditions, and medical support of newly diagnosed occupational pneumoconiosis (hereinafter referred to as pneumoconiosis) patients in Zhangdian District, Zibo City. Methods A total of 1 189 newly diagnosed pneumoconiosis patients in Zhangdian District from 1956 to 2019 were selected as the study subjects using retrospective method. Data of their age of onset, years of occupational exposure, category of working industry, type of pneumoconiosis, and status of medical support was collected and analyzed. Results The median and the 25th-75th percentiles [M (P25, P75)] of the age of onset were 51.8 (45.5, 56.1) years, and the mortality was 37.0%. The majority of pneumoconiosis cases were silicosis (45.2%) and coal workers' pneumoconiosis (39.8%). The highest prevalence of pneumoconiosis was in the coal mining and washing industry (42.4%), followed by manufacturing (33.4%). Pneumoconiosis patients in stage Ⅰ,Ⅱ, and Ⅲ accounted for 89.1%, 8.7%, and 2.2%, respectively. The M (P25, P75) of the length of work exposed to dust were 24.1 (16.5, 29.9) years.The higher stage of pneumoconiosis the shorter of the length of work exposed to dust among these pneumoconiosis patients(all P<0.05). The overall survival rate, the 5-year survival rate and the 10-year survival rate of these pneumoconiosis patients were 63.0%, 92.3% and 85.9%, respectively. Among the 749 surviving cases, 60.8% were aged 60.0 to <80.0 years. In terms of social security, 100.0% surviving cases enjoyed basic medical insurance, meanwhile, 96.1% and 81.8% patients were covered by major medical insurances and occupational injury insurances, respectively. The M (P25, P75) of age at death were 73.1 (64.0, 77.1) years. The main causes of death were respiratory diseases (59.3%) and malignant tumors (20.4%). Conclusion The prevalent types of pneumoconiosis in Zhangdian District, Zibo City, are coal workers' pneumoconiosis and silicosis. Medical support and assistance are relatively limited. The pneumoconiosis prevention and control focus should be on silicosis and coal workers' pneumoconiosis, particularly in the manufacturing industry.
7.Audiological Characteristics in 832 Deaf Children with Biallelic Causative Mutations in GJB2,SLC26A4 Gene
Qingjia CUI ; Guojian WANG ; Yuan ZHANG ; Ying YANG ; Dongyang KANG ; Yanshun DU ; Liping ZHAO ; Shasha HUANG ; Wei ZHANG ; Xibin SUN ; Pu DAI ; Lihui HUANG
Journal of Audiology and Speech Pathology 2014;(2):120-123
Objective To determine the audiological characteristics in 832 deaf children with biallelic causative mutations in GJB2 ,SLC26A4 gene .Methods The 832 patients received deafness gene screening ,553 were GJB2 gene biallelic causative mutations ,279 were SLC26A4 gene biallelic causative mutations .Patients were divided into four groups according to ages of hearing loss onset :<1 ,1~3 ,3~6 ,6~12 years old ,and the audiological character-istics and prevalence of GJB2 ,SLC26A4 gene mutations at different ages of onset .Results The prevalence of GJB2 gene mutations at four groups was 37 .97% (210/553) ,38 .34% (212/553) ,16 .27% (90/553) ,7 .41% (41/553) ,re-spectively ;the prevalence of SLC26A4 gene mutations at four groups was 25 .45% (71/279) ,44 .80% (125/279) , 20 .07% (56/279) ,9 .67% (27/279) ,respectively .The difference between GJB2 and SLC26A4 gene was significant(P=0 .001) .The prevalence of profound hearing loss with GJB2 gene mutations at four groups were 66 .67% (140/210) ,61 .32% (130/212) ,47 .78% (43/90) ,41 .46% (17/41) ,respectively .The difference was significant (P=0 .004) ,while the difference in 279 patients with SLC26A4 gene mutations was not statistically significant (P= 0 . 083) .Conclusion The age of hearing loss onset in patients with biallelic causative mutations in GJB 2 or SLC26A4 gene refers to 0~3 years -old ,hearing loss in patients with GJB2 ,SLC26A4 gene mutations gives priority to pro-found .The age of hearing loss onset is smaller ,the ratio of profound hearing loss is higher .Patients with severe and profound hearing impairment should be performed the genetic testing when the age of onset under 12 .
8.Medical road with you, with love——Application of multiple models in health education
Chinese Journal of Primary Medicine and Pharmacy 2020;27(18):2177-2178
Completing the building of a moderately prosperous society in all respects involves various aspects, but it is an imperative task to strengthen areas of weakness.China is a developing country with relatively insufficient medical resources.Yet without health for all, there can be no well-off society for all.The incidence of cancer has been among the top three, playing an important role in the work of national health.Among them, the department of oncology of the First Affiliated Hospital of Anhui University of Technology takes care of cancer patients by holding public lectures——famous doctors' lecture hall, establishing family poverty alleviation wards, establishing " cloud medical treatment" ——WeChat group and distributing brochures during tumor publicity week. All the methods are creative, evaluable and sustainable.It will be further improved in the future to provide more help for cancer patients.
9.Relationship Between Pathogenesis of "Kidney Deficiency and Blood Stasis in Collateral, Miniature Mass of Renal Collateral" and Autophagy Dysfunction in Renal Interstitial Fibrosis
Jiansheng LI ; Yingming WANG ; Yanshun YAN ; Jianlin CHENG ; Wennian ZHANG ; Guilan KANG
Chinese Journal of Experimental Traditional Medical Formulae 2023;29(2):186-194
Renal interstitial fibrosis (RIF) is the main pathological feature of chronic kidney disease caused by a variety of factors. "Kidney deficiency and blood stasis in collateral, miniature mass of renal collateral" is the main pathogenesis of RIF. The deficiency of healthy Qi will influence the kidney Qi, resulting in kidney deficiency and unsmooth qi transformation. As a result, phlegm, heat, stasis, toxin and other excess pathogens block the kidney collaterals, forming miniature masses. The masses accumulate in the renal collaterals, finally leading to RIF. Autophagy is a key process that keeps your body's cells in proper balance by taking aged or damaged components in a cell and recycling them. It is involved in the occurrence and development of RIF. The metabolism of excess pathogens such as phlegm, heat, stasis, and toxin in vivo is related to the degradation and reabsorption of autophagy. Autophagy is a way to eliminate phlegm, heat, stasis, toxin and other excess pathogens. Autophagy dysfunction will cause the accumulation of phlegm, heat, blood stasis, toxin and other excess pathogens, further the stasis of the kidney collaterals, miniature mass in kidney, and finally RIF. Kidney deficiency and blood stasis in collateral are the root cause of autophagy dysfunction, and the miniature mass of renal collateral is the manifestation of autophagy dysfunction. Autophagy dysfunction and miniature mass of renal collateral have the same pathological evolution. In this paper, based on the pathogenesis of "kidney deficiency and blood stasis in collateral, miniature mass of renal collateral" of RIF and RIF-autophagy relationship, this paper discusses the "kidney deficiency and blood stasis in collateral-autophagy dysfunction-miniature mass of renal collateral" relationship in RIF and comprehensively interprets the scientific connotation of the pathogenesis of "kidney deficiency and blood stasis in collateral, miniature mass of renal collateral", which is expected to lay a basis for explaining the role of autophagy in TCM theory and for the treatment of RIF and research on the mechanism.
10.Role of Autophagy in Renal Interstitial Fibrosis and Intervention of Chinese Medicine: A Review
Jiansheng LI ; Yingming WANG ; Yanshun YAN ; Jianlin CHENG ; Wennian ZHANG ; Guilan KANG
Chinese Journal of Experimental Traditional Medical Formulae 2022;28(19):274-282
Renal interstitial fibrosis(RIF)is a common pathway for the progression of chronic kidney disease to renal failure,and its pathogenesis is mainly related to renal inflammatory damage,oxidative stress,apoptosis,and excessive extracellular matrix(ECM) deposition. Transforming growth factor-β1(TGF-β1) signaling pathway,mammalian target of rapamycin(mTOR) signaling pathway and other signaling pathways mediate the occurrence and development of RIF. Because of the complicated mechanism of RIF,there have been no specific prevention and treatment measures in clinical practice. Autophagy is a non-damaging response produced by eukaryotic cells. It maintains the balance of tissue homeostasis through degradation and reabsorption. At present, Chinese medicine has achieved desirable clinical effects with its unique advantages of multiple components,multiple effects,and multiple targets in the treatment of chronic kidney disease to delay the process of RIF. Scholars have found that autophagy is consistent with the Yin-Yang theory and the theory of abdominal mass in traditional Chinese medicine (TCM) to a certain extent,and it is involved in many aspects of RIF. The progression of RIF is closely related to autophagy. The targeted therapy of RIF by intervention in autophagy has become the frontier of research. However,little is known about the role of autophagy in RIF and the regulation of autophagy by Chinese medicine in the treatment of RIF. Therefore,it is necessary to further elucidate the relationship between autophagy and RIF in order to clarify the mechanism of autophagy in RIF and the mechanism of Chinese medicine regulating autophagy in targeted therapy of RIF. This article focused on the correlation between autophagy and RIF based on TCM theory,and systematically summarized the role of autophagy in RIF and the intervention of Chinese medicine by combining the effects of autophagy on inflammation damage,oxidative stress,apoptosis,and excessive ECM deposition in RIF, and the regulation mechanism of autophagy in TGF-β1 and mTOR signaling pathways in RIF. This study was expected to provide a certain reference for the clinical treatment of RIF and the development of new drugs.